特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
939924

世界のプロテオミクスの各種提携契約:契約条件・合意内容(2010年~2020年)

Global Proteomics Partnering Terms and Agreements 2010 to 2020

出版日: | 発行: Current Partnering, a division of Wildwood Ventures Limited | ページ情報: 英文 400+ Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
世界のプロテオミクスの各種提携契約:契約条件・合意内容(2010年~2020年)
出版日: 2020年06月01日
発行: Current Partnering, a division of Wildwood Ventures Limited
ページ情報: 英文 400+ Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、プロテオミクスに関連する近年の各種提携契約について調査し、近年の傾向・動向、活発に提携契約を行う企業、主な大規模契約、各種提携契約の取引額・契約タイプ・技術区分・合意内容・目的・条件などの各種データをまとめています。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 ロテオミクス取引の動向

  • イントロダクション
  • 長年にわたって提携しているプロテオミクス
  • 最もアクティブなプロテオミクス取引メーカー
  • 取引タイプ別のプロテオミクス提携
  • 治療領域別のプロテオミクス提携
  • 業界別のプロテオミクス提携
  • プロテオミクス提携の取引条件
    • プロテオミクス提携契約総額
    • プロテオミクス別前払い
    • プロテオミクス取引のマイルストーン支払い
    • プロテオミクス使用料率
  • プロテオミクス取引の構造
  • a. ケーススタディ1:RRD InternationalとDipexium Pharmaceuticals
  • b. ケーススタディ2:HospiraとCempra Pharmaceutical
  • c. ケーススタディ3:アステラス製薬とOptimer Pharmaceuticals

第3章 プロテオミクスの主要取引

  • イントロダクション
  • 上位のプロテオミクス取引

第4章 最もアクティブなプロテオミクス取引メーカー

  • イントロダクション
  • 最もアクティブなプロテオミクス取引メーカー
  • 最もアクティブなプロテオミクス提携企業プロファイル

第5章 -プロテオミクス契約取引ディレクトリ

  • イントロダクション
  • プロテオミクス契約の取引ディレクトリ

第6章 技術タイプ別のプロテオミクス取引

第7章 提携リソースセンター

  • オンライン提携
  • 提携イベント
  • 取引決定に関するその他の資料

付録

目次
Product Code: CP2123

‘The Global Proteomics Partnering Terms and Agreements 2010 to 2020 report’ provides comprehensive understanding and unprecedented access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies.

‘The Global Proteomics Partnering Terms and Agreements 2010 to 2020 report’ provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in Proteomics partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Proteomics partnering contract documents
  • Top Proteomics deals by value

‘The Global Proteomics Partnering Terms and Agreements report’ provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Proteomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Proteomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual Proteomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of Proteomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Proteomics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Proteomics deals since 2010. Deals are listed by headline value, signed by big pharma, most active Proteomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Proteomics dealmaking with a brief summary followed by a comprehensive listing of Proteomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of proteomics partnering deals signed and announced since Jan 2010. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 lists proteomics deals by technology type.

In addition, a comprehensive appendix is provided organized by Proteomics partnering company A-Z, deal type definitions and Proteomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Proteomics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Proteomics technologies and products.

Report scope

‘Global Proteomics Partnering Terms and Agreements 2010 to 2020’ is intended to provide the reader with an in-depth understanding and access to Proteomics trends and structure of deals entered into by leading companies worldwide.

‘Global Proteomics Partnering Terms and Agreements 2010 to 2020’ includes:

  • Trends in Proteomics dealmaking in the biopharma industry since 2010
  • Analysis of Proteomics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Proteomics deals
  • Access to over 550 Proteomics deal records and contract documents where available
  • The leading antibody deals by value since 2010
  • Most active Proteomics dealmakers since 2010
  • The leading Proteomics partnering resources

In ‘Global Proteomics Partnering Terms and Agreements 2010 to 2020’, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

‘Global Proteomics Partnering Terms and Agreements 2010 to 2020’ provides the reader with the following key benefits:

  • In-depth understanding of Proteomics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Proteomics agreements with numerous real life case studies
  • Comprehensive access to Proteomics deals entered into by the world's biopharma companies, together with real world clause examples and contracts where available
  • Full listing of Proteomics deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading Proteomics deals by value since 2010
  • Identify the most active Proteomics dealmakers since 2010
  • Detailed access to actual Proteomics contracts enter into by the leading fifty big pharma and big biotech companies
  • Insight into the terms included in a Proteomics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Proteomics dealmaking

  • 2.1. Introduction
  • 2.2. Proteomics partnering over the years
  • 2.3. Most active Proteomics dealmakers
  • 2.4. Proteomics partnering by deal type
  • 2.5. Proteomics partnering by therapy area
  • 2.6. Proteomics partnering by industry sector
  • 2.7. Deal terms for Proteomics partnering
    • 2.7.1 Proteomics partnering headline values
    • 2.7.2 Proteomics deal upfront payments
    • 2.7.3 Proteomics deal milestone payments
    • 2.7.4 Proteomics royalty rates
  • 2.8. The anatomy of an Proteomics deal
  • 2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals
  • 2.8.b. Case study 2: Hospira & Cempra Pharmaceutical
  • 2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals

Chapter 3 - Leading Proteomics deals

  • 3.1. Introduction
  • 3.2. Top Proteomics deals by value

Chapter 4 - Most active Proteomics dealmakers

  • 4.1. Introduction
  • 4.2. Most active Proteomics dealmakers
  • 4.3. Most active Proteomics partnering company profiles

Chapter 5 - Proteomics contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Proteomics contracts dealmaking directory

Chapter 6 - Proteomics dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Proteomics deals by company A-Z
  • Appendix 2 - Proteomics deals by stage of development
  • Appendix 3 - Proteomics deals by deal type
  • Appendix 4 - Proteomics deals by therapy area
  • Appendix 5 -Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Proteomics partnering since 2010
  • Figure 2: Active Proteomics dealmaking activity sincce 2010
  • Figure 3: Proteomics partnering by deal type since 2010
  • Figure 4: Proteomics partnering by disease type since 2010
  • Figure 5: Proteomics partnering by industry sector since 2010
  • Figure 6: Proteomics deals with a headline value
  • Figure 7: Proteomics deals with an upfront value
  • Figure 8: Proteomics deals with a milestone value
  • Figure 9: Proteomics deals with a royalty rate value
  • Figure 10: Top Proteomics deals by value since 2010
  • Figure 11: Most active Proteomics dealmakers since 2010
  • Figure 12: Proteomics partnering by technology type since 2010
  • Figure 13: Online partnering resources
  • Figure 14: Forthcoming partnering events
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.